Korean J Dermatol.
2008 Jan;46(1):141-143.
Cutaneous Adverse Effects Associated with Sorafenib Therapy (Nexavar(R), BAY 43-9006)
- Affiliations
-
- 1Department of Dermatology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. jmyang@smc.samsung.co.kr
Abstract
- Sorafenib (Nexavar(R), BAY 43-9006) is a new oral multi-targeted tyrosine kinase inhibitor developed to delay disease progression in advanced solid organ malignancies and metastatic melanoma. Among the many reported toxicities attributed to sorafenib, dermatologic events, such as skin rash, acral erythema, alopecia and xerosis are the most frequently observed side effects. Recently, we experienced a case of a 41-year-old man who presented with generalized maculopapular erythematous eruptions, and acral erythema after sorafenib treatment for his metastatic hepatocellular carcinoma. Herein, we report the case and discuss the undesirable side effects of sorafenib.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Sorafenib (Nexavar(R), BAY 43-9006)-induced Hand-foot Skin Reaction with Facial Erythema
- Multiple Epidermal Cysts in a Hepatocellular Carcinoma Patient Taking Nexavar®
- Toxic Epidermal Necrolysis Associated with Sorafenib and Tosufloxacin in a Patient with Hepatocellular Carcinoma
- A Case of Leukocytoclastic Vasculitis after Use of Sorafenib (Nexavar(R))
- Treatments Other than Sorafenib for Patients with Advanced Hepatocellular Carcinoma
